Hrs-7450
Cerebral Stroke
Fujian Shengdi Pharmaceutical Co., Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Cerebral Stroke cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nxy-059 AstraZeneca | Phase 3 | BB |
Sovateltide Pharmazz, Inc. | Phase 3 | BB |
Reboxetine Universitätsklinikum Hamburg-Eppendorf | Phase 4 | B |
ax200 Axaron Bioscience AG | Phase 2 | B |
Dapsone Cidat, S.A. de C.V. | Phase 2/3 | B |
Astaxanthine Indonesia University | Phase 1 | CC |
Carbon Dioxide Imperial College London | N/A | D |
Same molecule, other indications
Hrs-7450 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →